Dr. Blay Discusses the Treatment Landscape of Sarcoma

Jean-Yves Blay, MD, PhD
Published: Tuesday, Mar 21, 2017



Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.

From a clinical research standpoint, it is very difficult to develop trials for sarcoma due to its variability between patients. The rarity of this disease must be adapted to the research of it, says Blay. Sarcoma has been shown to be a good model in which to develop treatments, adds Blay, demonstrated by the success of eribulin (Halaven) in liposarcoma.
 


Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses the treatment landscape of sarcoma.

From a clinical research standpoint, it is very difficult to develop trials for sarcoma due to its variability between patients. The rarity of this disease must be adapted to the research of it, says Blay. Sarcoma has been shown to be a good model in which to develop treatments, adds Blay, demonstrated by the success of eribulin (Halaven) in liposarcoma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x